Table 1.

List of commercial (FDA-approved) and likely-to-be commercial (completed phase III clinical trial) nano-based drugs in USA to treat cancer and brain diseases. Adapted from Reference 5 and 6.

Name	Company	Material	Drug	Disease/s	Approved
Doxil/Caelyx	Janssen	Liposome	Doxorubicin	Kaposi sarcoma Ovarian cáncer Multiple myeloma	1995 2005 2008
DaunoXome	Galen Pharma	Liposome	Daunorubicin	Kaposi sarcoma	1996
DepoCyt	Sigma Tau	Liposome	Cytarabine	Lymphomatous meningitis	1999
Myocet	Elan Pharma	Liposome	Doxorubicin	Breast cancer	2000
Lipodox (generic Doxil)		Liposome	Doxorubicin	Same as Doxil	2013
Marqibo	Onco TCS	Liposome	Vincristine	Acute Lymphoma Leukemia	2012
Onivyde	Merrimack	Liposome	Irinotecan	Pancreatic cancer	2015
Vyxeos	Jazz Pharma	Liposome	Daunorubin Cytarabine	Acute Myeloid leukemia	2017
Oncaspar	Enzon Pharma	Polymer	.Aspargase	Acute Lymphoblatic eukemia	1994
Copaxone	Teva	Polymer	Glatiramer acetate (synthetic protein)	Multiple sclerosis	1996
Eligard	Tolmar	Polymer	Leuprolide acetate	Prostate cancer	2002
Plegridy	Biogen	Polymer	PEG-Interferon beta-1a	Multiple sclerosis	2014
Glatopa (Generic Copaxone)	Novartis	Polymer	Glatiramer acetate (synthetic protein)	Multiple sclerosis	2015
Ontak	Cisai Inc	protein	Denileukin diftitox (Synthetic protein)	Cutaneous T-cell lymphoma	1999
Abraxane	Celgene	protein	Paclitaxel	Breast Cancer NSCLC Pancreatic cancer	2005 2012 2013
Invega Sustenna	Janssen	nanocrystals	Paliperidone Palmitate	Schizophrenia	2009
Nanotherm	MagForce	Inorganic	Iron oxide	Glioblastoma	2010
Onpattro	Alnylam Pharmaceuticals	Lipid/Liposome	Patisiran (ALN-TTR02)	hATTR Amyloidosis	2018
ThermoDox	Celsion	Liposome,	Doxorubicin	Hepatocellular carcinoma	Phase III completed ClinicalTrials.gov identifier#NCT00617981
Paclical	Oasmia Pharma	Polymer	Paclitaxel, Doxil	Ovarian cancer	Phase III completed. ClinicalTrials.gov identifier# NCT00989131
NK-105	Nippon Kayaku	Polymer	Paclitaxel	Breast cancer	Phase III completed ClinicalTrials.gov identifier# NCT01644890